drugset / Trial / NCT05632328
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Phase 2
Active not recruiting
24 enrolled
Bruno Bockorny
Agenus Inc. · collabDana-Farber Cancer Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Botensilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least one previous line of cancer therapy. The names of the study drugs involved in this study are: * AGEN1423 * Botensilimab Participants will receive study treatment for about 2 years and will be followed for 1 year after.
Timeline
- Start
- 2024-08-08
- Primary completion
- 2026-08-04
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGEN1423 | Unknown | — | Intravenous |
| Subject | Botensilimab | Monoclonal antibody | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |